undamentalytics Newsletter
Sign in

Niagen Bioscience, Inc. revenue

Niagen Bioscience, Inc.'s revenue was $129m in fiscal 2025, up 29.9% on the year before. Since fiscal 2010 ($7.6m) it has grown at a compound 20.8% a year. Over the last twelve months it was $129m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jan 20112011Dec 20112012Dec 20122013Dec 20132014Jan 20152015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue88121015182221324659677284100129129
Growth on the year before—+7.2%+43.1%−12.5%+50.7%+16.8%+21.1%−2.1%+48.8%+46.7%+28.0%+13.8%+6.8%+16.0%+19.2%+29.9%—
Gross profit3223581010162635414351628383

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Consumer Products $97.7M 75.5% ▲ 27.2%
Ingredients $28.7M 22.2% ▲ 44.7%
Analytical Reference Standards and Services $3.1M 2.4% ▲ 2.2%
Pharmaceuticals $0 0.0% —

From Niagen Bioscience, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Niagen Bioscience, Inc. $129m 11.0% 16.8%
Zevra Therapeutics, Inc. $136m 119.4% 101.9%
Natural Alternatives International Inc $143m 9.7% -2.6%
Heron Therapeutics, Inc. $151m 1.0% 8.6%
Eton Pharmaceuticals, Inc. $106m 81.5% 53.8%
Amarin Corp plc\uk $176m -22.3% -18.3%

Compare with peers

Head to head: NAGE vs ZVRANAGE vs NAIIHRTX vs NAGEETON vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Niagen Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Niagen Bioscience, Inc.